Jaggi R, Höck W, Ziemiecki A, Klemenz R, Friis R, Groner B
Ludwig Institute for Cancer Research, Bern Branch, Inselspital, Switzerland.
Cancer Res. 1989 Apr 15;49(8 Suppl):2266s-2274s.
We have previously described the inhibition of glucocorticoid-dependent transcription from the mouse mammary tumor virus long terminal repeat promoter by products of the H-ras and v-mos oncogenes. We have studied the effects of conditional oncogenes on expression of glucocorticoid-dependent indicator genes. Expression of the glucocorticoid-dependent transcription of the tyrosine aminotransferase gene was monitored in FTO-2B rat hepatoma cells during Mr 21,000 protein (p21) H-ras induction. A strong transcriptional repression of the tyrosine aminotransferase gene followed p21 H-ras expression. The sequences in a glucocorticoid-dependent promoter which are responsible for the oncogene-mediated repression could be localized to the glucocorticoid response element; a construct in which a 15-base pair glucocorticoid response element was inserted 5' of the thymidine kinase promoter exhibited the oncogene-mediated repression of transcription. We observed a strong repression of glucocorticoid-dependent promoters and promoter constructs not only in the presence of p21 H-ras and p37 v-mos but also with p60 v-src. p57 v-myc, however, had no effect. Oncogene expression is not a sufficient prerequisite for an initial repression of glucocorticoid hormone-dependent gene transcription, since even in the presence of constitutively high levels of oncogene product a transient stimulation of glucocorticoid-dependent gene expression was found. Protein synthesis inhibition experiments revealed that no hormonally induced cellular protein is needed for the oncogene-mediated repression. It seemed reasonable that this phenomenon might reflect oncogene effects on the glucocorticoid receptor. We, therefore, made measurements of the glucocorticoid receptor protein. In the presence of glucocorticoid hormone the receptor translocated rapidly from the cytoplasm to the nucleus. In normal NIH 3T3 cells, after 24-h treatments the nuclear receptor levels had declined to about 50% of those determined at 2 h and in the presence of p21 H-ras they declined to 15%. The levels of cytoplasmic receptor were not affected by p21 H-ras expression.
我们之前曾描述过,H-ras和v-mos癌基因的产物可抑制小鼠乳腺肿瘤病毒长末端重复启动子的糖皮质激素依赖性转录。我们研究了条件性癌基因对糖皮质激素依赖性指示基因表达的影响。在诱导Mr 21,000蛋白(p21)H-ras期间,在FTO-2B大鼠肝癌细胞中监测酪氨酸转氨酶基因的糖皮质激素依赖性转录表达。p21 H-ras表达后,酪氨酸转氨酶基因出现强烈的转录抑制。糖皮质激素依赖性启动子中负责癌基因介导的抑制作用的序列可定位于糖皮质激素反应元件;在胸苷激酶启动子5'端插入15个碱基对糖皮质激素反应元件的构建体表现出癌基因介导的转录抑制。我们观察到,不仅在存在p21 H-ras和p37 v-mos时,而且在存在p60 v-src时,糖皮质激素依赖性启动子和启动子构建体都受到强烈抑制。然而,p57 v-myc没有影响。癌基因表达并非糖皮质激素依赖性基因转录初始抑制的充分前提条件,因为即使在存在组成性高水平癌基因产物的情况下,也发现糖皮质激素依赖性基因表达有短暂刺激。蛋白质合成抑制实验表明,癌基因介导的抑制不需要激素诱导的细胞蛋白。这种现象可能反映了癌基因对糖皮质激素受体的影响,这似乎是合理的。因此,我们对糖皮质激素受体蛋白进行了测量。在存在糖皮质激素的情况下,受体迅速从细胞质转运到细胞核。在正常的NIH 3T3细胞中,经过24小时处理后,核受体水平降至2小时时测定值的约50%,而在存在p21 H-ras时,它们降至15%。细胞质受体水平不受p21 H-ras表达的影响。